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Abstract: Anti-angiogenic therapy is an old method to fight cancer that aims to abolish the nutrient
and oxygen supply to the tumor cells through the decrease of the vascular network and the avoidance
of new blood vessels formation. Most of the anti-angiogenic agents approved for cancer treatment rely
on targeting vascular endothelial growth factor (VEGF) actions, as VEGF signaling is considered the
main angiogenesis promotor. In addition to the control of angiogenesis, these drugs can potentiate
immune therapy as VEGF also exhibits immunosuppressive functions. Despite the mechanistic
rational that strongly supports the benefit of drugs to stop cancer progression, they revealed to
be insufficient in most cases. We hypothesize that the rehabilitation of old drugs that interfere
with mechanisms of angiogenesis related to tumor microenvironment might represent a promising
strategy. In this review, we deepened research on the molecular mechanisms underlying anti-
angiogenic strategies and their failure and went further into the alternative mechanisms that impact
angiogenesis. We concluded that the combinatory targeting of alternative effectors of angiogenic
pathways might be a putative solution for anti-angiogenic therapies.
Keywords: neo-angiogenesis; anti-angiogenic therapy; cancer therapy; VEGF; new targets; drug re-
sistance
1. Introduction
Cancer angiogenesis is a complex process of a new and abnormal blood vessels net-
work formation that accounts for tumor growth and metastasis [1,2]. The angiogenic
switch that stimulates endothelial cells (ECs) proliferation and migration to form new
blood vessels during tumor growth is promoted by the constant release of pro-angiogenic
factors by cancer cells and by cancer-associated stromal cells (e.g., macrophages, fibroblasts,
neutrophils, adipocytes) [3–7]. During this process, the increased proliferation of ECs leads
to the formation of a disorganized and immature vascular network with disrupted ECs junc-
tions, pericytes detachment and without a continuous basement membrane, responsible
for tumor neo-vessels permeability, interstitial fluid pressure, and fragility [1,2,8,9].
While different molecular mediators are important in the control of cancer angiogene-
sis, the vascular endothelial growth factor (VEGF-A, also known as simply VEGF) is by far
the most well studied and targeted in cancer therapy.
Anti-Angiogenic Therapy, Focused on VEGF, for Cancer Treatment
In 1971, Folkman hypothesized that anti-angiogenic therapy would be beneficial
for cancer treatment since it could disrupt the pre-existing blood vessels and avoid the
formation of new ones, decreasing oxygen and nutrient supply to cancer cells, and conse-
quently decelerating tumor growth [10–13]. Decades after Folkman’s statement, antibodies
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such as bevacizumab, the first VEGF-targeted agent approved by the Food and Drug
Administration (FDA) for cancer treatment, was available for cancer therapy [12].
In cancer, neo-angiogenesis is essential for tumor growth and for metastatic pro-
cesses [11,14–17]. Despite the existence of other signaling pathways involved in angiogen-
esis, VEGF/VEGFRs interaction has been considered as a key regulator and constituted
an attractive and central target for the development of anti-angiogenic drugs [18–22], the
blockade of VEGF signaling pathway by neutralizing antibodies to VEGF or to VEGFRs, sol-
uble VEGFR hybrids, or inhibitors of VEGFRs tyrosine kinase (RTKi) seems to be ineffective
as a monotherapy, and resistance is a common event in cancer patients [23]. Therefore, the
major challenge in VEGF-targeted therapies is to overcome resistance, due to adaptive and
compensatory mechanisms (Figure 1). The limited success of single-targeted monotherapy
approaches can be justified by six different mechanisms: (1) The activation of alternative
angiogenic signaling pathways; (2) the upregulation of other pro-angiogenic factors [24–28];
(3) the vascular co-option, a process where cancer cells proliferate near the existing blood
vessels, avoiding further angiogenesis [29,30]; (4) the vascular mimicry, in which cancer
cells acquire an endothelial-like phenotype and led to the formation of blood vessels with-
out ECs involvement [31–33]; (5) the endothelial progenitor cells recruitment [34,35], and
(6) the increased mobilization of other cell types with a pro-inflammatory/pro-angiogenic
phenotype [36]. Supported by this knowledge, a new generation of drugs was developed
in order to improve anti-tumoral efficacy, by the simultaneously targeting VEGF signaling
pathway and alternative angiogenic pathways. For instance, in vitro and in vivo results
showed that the dual targeting of VEGF and fibroblast growth factor (FGF) pathway in-
hibited ECs proliferation and migration [37]. Moreover, the design and development of
new anti-VEGF signaling drugs continues, including the arylamide-5-anilinoquinazoline-8-
nitro derivative a recent inhibitor of VEGFR2-kinase activity with in vitro anti-tumor and
anti-angiogenic activity [38].
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Figure 1. Pro-angiogenic factors released by cancer cells and tumor microenvironment (TME) are essential for neo-
angiogenesis promotion, tumor growth, vascular co-option or vascular mimicry. Neo-angiogenesis is stimulated by the
release of pro-angiogenic factors by cancer cells or by other cells in the tumor microenvironment (TME), as macrophages,
stromal cells, and fibroblast. Among the positive regulators, vascular endothelial growth factor (VEGF) is the most well-
studied, and it is almost ubiquitously present at angiogenesis sites. Once it binds to its tyrosine kinases receptors (VEGFRs),
they become activated and form homo- or heterodimers, triggering intracellular signaling cascades to stimulate ECs’
proliferation, migration, differentiation, tube formation, and permeability control. Besides VEGF, other pro-angiogenic
factors as fibroblast growth factor (FGF), platelet-derived growth factor (PDGF), placental growth factor (PIGF), and
hepatocyte growth factor (HGF) are essential for endothelial tip cell activation (endothelial cell (EC)) that respond and
guide EC migration in the direction of a pro-angiogenic stimulus, thereby promoting neo-angiogenesis). Moreover, a key
process during EC migration is the formation of filopodia (actin-rich cellular protrusions) in tip cells, that will guide ECs
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towards the pro-angiogenic rich microenvironment. Nowadays, the employment of anti-angiogenic drugs for cancer
treatment has been disappointing, in part because most drugs are VEGF-centered. VEGF blockade triggers compensatory
mechanisms, such as the upregulation of other pro-angiogenic factors expression and the activation of other angiogenic
signaling pathways, leading to patient resistance to VEGF signaling pathway blockade. During vascular co-option, tumor
cells migrate along the preexistent blood vessels (specially tumor cells, rich in myofibroblasts), taking over of the existing
vasculature to tumor blood supply. This process is essentially reported in highly vascularized tumors, as brain, lung, and
liver. Vascular mimicry is characterized by a phenomenon resembling tumor blood supply independently of angiogenesis or
endothelial cells (ECs), being correlated with poor patient survival. During this process, cancer cells acquire endothelial-like
properties and organize into vascular-like structures acting as a system to obtain nutrients and oxygen, independently of
normal blood vessels or neo-angiogenesis. FGF: Fibroblast growth factor; FGFR: Fibroblast growth factor receptor; HGF:
Hepatocyte growth factor; PDGF: Platelet-derived growth factor; PDGFR: Platelet-derived growth factor receptor; PIGF:
Placental growth factor; PIGFR: Platelet-derived growth factor receptor; VEGF: Vascular endothelial growth factor; VEGFR:
Vascular endothelial growth factor receptor.
2. Targeting Alternative Angiogenic Signaling Pathways to Weaken Cancer
VEGF blockers act on the recognition and neutralization of all bioactive forms of
VEGF, preventing VEGFRs activation and consequently inhibiting tumor growth [39].
However, compensatory mechanisms of other angiogenic mediators may be responsible
for patients’ resistance to VEGF signaling pathway blockage (Figure 1). For instance, in
metastatic colorectal cancer patients, bevacizumab was associated with increased plasma
levels of placental growth factor (PIGF), FGF, and platelet-derived growth factor (PDGF),
prior or along disease progression [40,41]. Other studies have been reporting the tumor
vessels normalization in hepatocellular carcinoma models and the improved efficacy of
VEGF-targeted therapy in ocular disease as outcomes of PIGF blockage [42].
Thus, increased levels of other pro-angiogenic factors may compensate VEGF blockage
(Figure 1) and trigger alternative VEGF-independent angiogenic pathways.
2.1. Fibroblast Growth Factors (FGFs)
FGFs are known as potent angiogenic inducers that increase the proliferation and the
migration of ECs [43]. FGF family of tyrosine kinase receptors (FGFR, type V RTK) act
upon homo- and heterodimers formation. FGFRs present Ig-like loops in the extracellular
domain, which can form covalent dimers through disulfide bonds and promote their
constitutive activation [44].
In many cancer types, the anti-VEGF resistant tumors present increased expression of
FGF and/or FGFR upon hypoxia [45,46] that contributes for the synergistic cooperation
of FGF/FGFR and VEFG/VEGFR axes to the amplification of tumor angiogenesis [25]. In
preclinical studies, the application of dual inhibitors of FGF and VEGF pathways have
shown an increased anti-cancer efficacy [25,47–50]. Several inhibitors targeting VEGF
and other RTK pathways have been tested, including: Brivanib (dual FGF/VEGF- RTKi),
which increases the overall survival (OS) of pancreatic neuroendocrine tumors mouse
models; dovitinib (VEGF, FGF and PDGFRs- RTKi) that delays tumor growth; and S49076
(MET, AXL, and FGF RTKi) that induces tumor growth arrest in bevacizumab-resistant
tumors [47,49,50]. Nevertheless, in clinical settings after anti-VEGF therapy recurrence,
both dovitinib (VEGF, FGF and PDGF RTKi) and nintedanib (VEGF, FGF and PDGF RTKi)
were shown to be ineffective [51–53]. New applications for old drugs have also been tested
in the control of cancer angiogenesis. Thalidomide is a good and promising example,
as the teratogenic effect of thalidomide is due to the prevention of the embryo normal
angiogenesis through the interference with FGFs [54]. Therefore, the use of thalidomide and
analogues as anti-angiogenic drugs has been a focus of cancer research [55,56]. Thalidomide
was associated to anti-angiogenic effects in a mice model of neuroblastoma and to decreased
tumor growth, metastasis, and angiogenesis in breast cancer [57,58]. Thalidomide also
increases the remodeling and stabilization of the abnormal tumor vasculature, in a process
mediated by FGF inhibition [59–61]. This drug has been also pointed out as a suitable
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alternative as an anti-angiogenesis effective drug [62], involving the downregulation of
FGF and VEGF production [63], in multiple myeloma.
2.2. Angiopoietins (ANG)
ANG1 is an angiogenesis suppressor involved in the maturation and stabilization of
blood vessels through Tie2 receptor activation (Type XII RTKs) and in the perivascular-ECs
interaction and ECs survival [64–66]. However, ANG1 also seems to limit the continuous
angiogenesis in the tumor and consequently contribute for tumor growth inhibition [67].
ANG1 might be useful in a vascular improvement-based cancer therapy, aiming to the
stabilization of the tumor vasculature and further improvement of drug delivery.
On the contrary, ANG2 (mostly produced by ECs) acts as an endogenous antagonist
of ANG1 function that leads to remodeling processes or vascular sprouting in response to
VEGF [68]. The angiogenic pattern activated by ANG2 resembles the cancer angiogene-
sis, which is characterized by unstable and leakier vessels [69]. ANG2 is upregulated in
many cancer types and has been associated with poor survival and with more invasive
phenotypes, which indicates a crucial role in the development of resistance to anti-VEGF
therapy [70–72]. Colorectal cancer patients with poor responses to bevacizumab had
increased ANG2 serum levels, and VEGF and ANG2 blockage in vivo delayed tumor
growth, normalized tumor vasculature and increased the survival of mice with glioblas-
toma [73–75]. In pre-clinical studies, the dual VEGF/ANG2 blockage has been shown to
suppress revascularization and tumor progression, but their clinical efficacy using vanu-
cizumab (humanized VEGF/ANG2 bi-specific monoclonal antibody) is still under Phase I
human trials, though with promising results [75–78].
2.3. Platelet-Derived Growth Factor (PDGF)
In different cancer types aberrant PDGF signaling leads to the secretion of pro-
angiogenic factors, promoting an increase in ECs proliferation, migration, sprouting, and
tube formation, with a consequent stimulation of lymph-angiogenesis and lymphatic
metastasis [77–80]. PDGF signaling is associated with tumor vascularization in ovarian,
non-small-cell lung carcinoma (NSCLC), and hepatocellular carcinoma [79,80]. In glioblas-
toma, the increased expression of PDGFR is related to poor prognosis [81], and the dual
inhibition of VEGF/PDGFR improves survival in mice models [81,82]. In vitro, ponatinib, a
multi-tyrosine kinase inhibitor including PDGFR inhibitor, reduces the viability, migration,
and tube forming capacity of human umbilical vein ECs (HUVECs) [83]. In the future, the
use of PDGF inhibitors might have a place in the portfolio of therapeutic options for the
improvement of clinical efficacy of VEGF blockers [84,85].
2.4. Hepatocyte Growth Factor (HGF)/c-MET
HGF/c-MET signaling pathway (type X TKR) regulates cell proliferation, motility,
and survival, also being a mediator of tumor growth and neo-angiogenesis [86]. In a cancer
context, HGF/c-MET activation exerts pro-angiogenic effects, leading to a direct activation
of ECs and an indirect stimulation of other pro-angiogenic factors, as VEGF [87]. HGF/c-
MET has a role in anti-VEGF therapy resistance and bevacizumab-resistant patients exhibit
an upregulation of c-MET expression [88]. In cancer models, it was proven that HGF/c-
MET is responsible for the resistance to anti-VEGF therapy with sunitinib (VEGFR and
PDGFR RTKi), while the concomitant exposure to HGF/c-MET inhibitors and sunitinib
abrogated angiogenesis and tumor growth [89]. In patient-derived glioblastoma cells,
VEGF blockage restores MET activity, and c-MET inhibition decreases the invasive capacity
of glioblastoma cells [90]. Unfortunately, the concomitant use of onartuzumab (anti-c-MET)
with bevacizumab brought no additional clinical benefits [91,92].
2.5. Placental Growth Factor (PIGF)
PIGF is a member of the VEGF family that binds to VEGFR1 and its co-receptors
neuropilin-1 and 2 (NRP1 and NRP2). PIGF has been indicated as a putative player
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in anti-VEGF agents resistance since some reports showed its upregulation in patients
subjected to anti-VEGF therapy [93–95]. Moreover, aflibercept (or ziv-aflibercept), a drug
that neutralizes both VEGF and PIGF, showed to be effective in cancer patients-derived
xenografts models [96].
2.6. Alternative Anti-Angiogenic Factors
In normal conditions, naturally anti-angiogenic factors, such as thrombospondin (TSP-
1 and 2), pigment epithelium-derived factor (PEDF), and endostatin, play an important
role in the counterbalance of pro-angiogenic factors, through the blockade of multiple
pro-angiogenic factors and endothelial cell apoptosis [97]. Given that and considering that
the expression of those factors in tumors is often low, there was an increasing interest in
the application of these factors and its derivatives as potential anticancer agents [97].
TSP is amongst the first described angiogenesis inhibitors [98], and different attempts
were already made to validate TSP and analogs as anti-angiogenic modulators for thera-
peutic use. For instance, although ATB-510, a TSP mimetic peptide, in a phase I clinical
trial showed a favorable low toxicity profile in patients with various solid tumors [99,100],
in a posterior phase II trial in soft tissue sarcoma and stage IV melanoma patients ATB-510
did not show efficacy as a monotherapy, since no improvement in patients outcome was
achieved [101–103]. Likewise, a recombinant version of the three thrombospondin repeat
(TSR) domains designated 3TSR was shown to normalize tumor vasculature and to po-
tentiate the tumor regression mediated by chemotherapy [104], reinforcing that a stable
vasculature potentiates the anti-cancer therapy by allowing a more effective drug delivery.
PEDF is a multifunctional member of the serine proteinase inhibitor (serpin) family
and it plays a role as an inhibitor of angiogenesis [105]. The use of PEGF as a drug has been
explored, and different phosphomimetic mutants [106,107] and post-translational modified
variants [108,109] with enhanced anti-angiogenic activity were already developed. These
strategies have focused mainly on eye disease [110] and wound healing [111], but their
application in cancer therapy is under debate [112,113].
Endostatin is a C-terminal fragment of type XVIII collagen and it is the strongest
endogenous inhibitor of angiogenesis [114,115], its use in cancer therapy being a promising
tool. The use of a recombinant human endostatin (Endostar) was approved by the State
Food and Drug Administration of China in 2005 for the treatment of NSCLC patients [116].
Since then, several studies have been relating the anti-cancer properties of this therapy for
a variety of other cancer types, including colorectal cancer, melanoma, and breast cancer,
whether as a monotherapy or in combination [117,118]. Despite being tested in clinical
trials since 2002 [119], further clinical studies are needed to confirm its safety and to better
understand endostatin mechanism of action and efficacy, since its effects are complex and
may interfere with several different mechanisms [115].
3. The Use of Anti-Angiogenic Agents in Cancer: A Disappointing
Therapeutic Strategy
The standard care of cancer patients with solid tumors is based on surgical resection
followed by chemotherapy and/or radiotherapy, in order to prevent cancer recurrence and
the progression of occult microscopic tumors [120–122]. However, therapy resistance is
still one of the major obstacles for the optimal success of cancer management is [123].
Given the central role of VEGF in the promotion of tumor angiogenesis, its targeting
has emerged as the most promising therapeutic strategy for angiogenesis inhibition and
cancer treatment. However, decades after Folkman’s statement, anti-angiogenic strategies
were developed, and antibodies such as bevacizumab are available for cancer therapy [12].
Nevertheless, so far these strategies have failed, at least in part because the precise molecu-
lar mechanisms of cancer neo-angiogenesis remain unclear. Additionally, a novel paradigm
emerges since some studies suggested that the abrogation of blood supply will restrict
drug delivery (e.g., cytostatic agents) to the tumor, decreasing their clinical efficacy [9].
Additionally, strategies focused on restoring tumor vessels normalization will increase the
penetration of therapeutic agents into the tumor, improving the efficacy of drugs [124,125].
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VEGF:VEGR axis is considered as the key mediator of pathophysiological angiogen-
esis. Overactivation of VEGF:VEGFR axis is a trait of many cancer types and correlates
with increased microvessel density (MVD) and metastatic spread [18–20,22,126]. The block-
age of the VEGF:VEGFR axis seems to be ineffective as monotherapy, and primary or de
novo resistance is a common feature in cancer patients [23,123]. At the molecular level,
the disappointing clinical results obtained by the use of VEGFR inhibitors could be ex-
plained by VEGF-independent compensatory mechanisms, though the activation of other
angiogenic signaling pathways (e.g., PDGF/PDGFR, FGF/FGFR, Ang/Tie2) (Figure 2)
and/or the upregulation of the expression of other pro-angiogenic factors (e.g., bFGF,
PDGF) [24–26,28,127]. This was clinically evident since cancer patients treated with beva-
cizumab increase the plasma levels of PIDF, FGF, and PDGF concomitantly with disease
progression [40,41]. Accordingly, the in vivo blockage of PIGF or FGF pathway normalizes
the tumor vessels and improves the efficacy of VEGF-targeted therapy [25,42,47–49,60].
Strategies focused on the dual inhibition of VEGF and other pro-angiogenic signaling
pathways might be pivotal for the improvement of anti-angiogenic cancer therapy. For
instance, in bevacizumab-resistant tumors, brivanib (dual FGF/VEGF inhibitor) increases
the overall survival (OS) in a mouse model of pancreatic neuroendocrine tumor, dovi-
tinib (VEGFR, FGFR and PDGR inhibitor) delays tumor growth, and S49076 (MET, AXL,
and FGFR kinase inhibitor) induces tumor growth arrest [47,49,50]. Additionally, in mice
models of cancer, the blockage of VEGF/ANG2 suppresses revascularization and tumor
progression and increases OS [74–76]. Although pre-clinical models showed increased
efficacy in tackling tumor angiogenesis, unfortunately the results in clinical settings are
not so favorable (Figure 2). The limited success of the anti-antigenic approaches may be
also related to the complexity of tumors vascularization processes, as the angiogenic-like
phenomena (see Subsection of Section 1) and the recruitment of EPCs (see Subsection of
Section 1) [29,30,34,35]. A better understanding on how tumors become vascularized and
how they escape from anti-angiogenic therapy will for sure open new perspectives for the
development of more effective anti-angiogenic approaches.
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Figure 2. Anti-angiogenic drugs can act as decoy agents, monoclonal antibodies, or tyrosine kinase inhibitors. Bevacizumab
was the first anti-angiogenic drug approved for human use, however, its use as monotherapy is inefficient. Compensatory
mechanisms of other angiogenic mediators induces a switch in the vascular endothelial growth factor (VEGF)-dependent
state to a VEGF-independent angiogenic process and leads to patient resistance to VEGF signaling pathway blockade.
Nowadays, a new class of drugs, by blocking other effectors in angiogenic signaling pathways, try to improve the clinical
efficacy of anti-angiogenic therapies. In some scenarios, the use of anti-angiogenic therapies delays the disease outcome
of cancer patients, still other patients do not have any additional benefits. The major signaling pathways downstream of
VEGFRs, FGFRs, PDGRs, and c-MET in endothelial cells (ECs) are PI3K-AKT-mTOR, Ras-Raf-MEK-ERK, and JAK-STATs,
which are pivotal for EC survival, proliferation, and migration. AKT: Protein kinase B; ERK: Extracellular-signal-regulated
kinase; FGF: Fibroblast growth factor; FGFR: Fibroblast growth factor receptor; HGF: Hepatocyte growth factor; JAK:
Janus protein tyrosine kinase; MEK: Mitogen-activated protein kinase; mTOR: Mammalian target of rapamycin; PDGF:
Platelet-derived growth factor; PDGFR: Platelet-derived growth factor receptor; PI3K: Phosphoinositide 3-kinases; Raf:
Serine/Threonine Kinase; STAT: Signal transducer and activator of transcription protein; VEGF: Vascular endothelial growth
factor; VEGFR: Vascular endothelial growth factor receptor.
4. The Versatile Use of Anti-VEGF Agents to Enhance Immunotherapies
VEGF, besides its role as a major driver of angiogenesis, can also have immuno-
suppressive functions, as the inhibition of immune effector cells and the promotion of
immunosuppressive cells. For instance, VEGF through the inhibition of NF-kB signaling
pathway is able to inhibit dendritic cell maturation and differentiation [128–130], and by
the upregulation of PD-L1 (programmed death-protein ligand 1) expression, it inhibits den-
dritic cell antigen-presentation function, suppressing the further activation and expansion
of T-cells [131]. Furthermore, Alfaro et al. demonstrated that VEGF inhibits monocytes
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differentiation into dendritic cells, being this inhibitory effect reversed upon bevacizumab
or sorafenib treatment (VEGFR and PDGFR RTKi) [132].
VEGF-dependent mechanisms promote the generation of an immunosuppressive
tumor microenvironment (TME), favoring cancer immune escape and cancer progres-
sion [133]. VEGF favors monocyte and macrophage recruitment to the TME [134,135], but
it inhibits the differentiation and proliferation of CD8+ cytotoxic T-cells [136,137]. VEGFR-
2 activation by VEGF on CD8+ cells induces the upregulation of immune checkpoint
molecules, such as PD-1, TIM-3 (T-cell immunoglobulin mucin receptor 3), and CTLA-4
(cytotoxic T lymphocyte antigen 4), leading to cytotoxic T-cell exhaustion [138]. In contrast,
VEGF promotes the proliferation of regulatory T-cells (Tregs), which are involved in tumor
development and progression by inhibiting anti-tumor immunity [139,140]. In fact, VEGF
levels are positively correlated with the percentage of Tregs, this effect being reversed
by VEGF/VEGFR2 blockade in a mouse model of colorectal cancer and by bevacizumab
administration in colorectal cancer patients [141,142]. The interaction between VEGF and
NRP1 also contributes to the generation of the immunosuppressive microenvironment.
Hansen et al. showed that the knockout of NRP1 in Foxp3+ Tregs reduced Tregs infiltration
into the TME, while it increased CD8+ cytotoxic T-cells, leading to prolonged survival in
melanoma bearing mice [143,144].
Considering the role of VEGF in the TME, the inhibition of VEGF-induced signaling
cascades can ideally suppress tumor growth through two mechanisms: By suppress-
ing angiogenesis and by exerting immunosuppressive effects [20,145]. Due to the dual
effect of VEGF on angiogenesis and in the tumor immune microenvironment, several
studies addressed the combinatory effect of anti-angiogenic therapies with immune check-
point blockade.
Cancer immunotherapy is based on the use of immune checkpoint inhibitors (ICIs)
directed against immune checkpoint molecules, vital components of immune homeosta-
sis [146]. Cancer cells are able to hijack the expression of these molecules, inducing immune
suppression and contributing to tumor evasion of immune surveillance [147,148]. The
most common targets of ICIs are the immune checkpoint molecules CTLA-4, PD-1, and
its ligands PD-L1 and PD-L2 [149]. Their blockade results in the removal of inhibitory
signals of T-cell activation, enhancing anti-tumor immune activity and leading to the
inhibition of tumor growth, through CD8+ T-cell mediated cancer cells death [150,151].
Although the use of ICIs enhances the immune system of the host towards the recognition
and attack of the tumor, the clinical usage of immunotherapy alone only benefit a small
subset of patients [152–154]. Given the decreased ICIs-cancer patient response and the
correlation between anti-angiogenic factors and immunity, anti-angiogenic therapies have
been considered as putative enhancers of ICIs treatment.
As previously mentioned, anti-VEGFRs are the first line therapy for patients with
metastatic renal cell carcinoma [155]. More recently, their use in combination with ICIs
has been tested. Two phase III clinical trials compared the effect of sunitinib versus the
combinatory therapy of axitinib (VEGFR and PDGFR RTKi) and pembrolizumab (anti-PD-1
monoclonal antibody) (NCT02853331) [155] and combined with avelumab (anti-PD-L1
monoclonal antibody) (NCT02684006) [156]. In both cases, the combination induced
a significantly increase in progression free survival (PFS) of cancer patients [149,157].
Additionally, the combination of axitinib and pembrolizumab ICI prolonged the OS of
cancer patients [149]. Interestingly, Wallin et al. observed an increase of intra-tumoral
antigen-specific CD8+ T-cells migration after the combination with bevacizumab and
atezolizumab (anti-PD-L1), in metastatic renal cell carcinoma patients [158].
Two clinical trials (phase I and phase II) are currently testing the combination of ipili-
mumab (anti-CTLA-4) and bevacizumab in melanoma patients (stage III-IV), focusing on
the effect on OS and PFS (NCT01950390) (ClinicalTrials.gov, started in 2013, accessed on 25
March 2021) [159] and on the maximum dose tolerated (NCT00790010) (ClinicalTrials.gov,
started in 2008, accessed on 25 March 2021) [160]. In mouse models of melanoma brain
metastasis, the combination of axitinib with anti-CTLA-4 antibodies increases the number
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of effector T-cells and antigen presentation by dendritic cells, which promotes a reduction
on tumor growth and an increase in OS [161]. A phase III clinical trial (IMpower150)
reported a significant improvement of PFS and OS in metastatic non-squamous subset of
NSCLC patients after the combined administration of atezolizumab, bevacizumab, and
chemotherapy (carboplatin and paclitaxel) [162]. This result expanded the application of
atezolizumab in NSCLC treatment, because its combinatory usage is effective regardless
PD-L1 expression [162,163].
Thus far, there is a large panel of promising preclinical and clinical studies ongo-
ing (Table 1). However, a better understanding of the mechanisms involved in both
immunotherapy and anti-angiogenic therapy will improve and open new perspectives on
the synergistic efficacy, cancer patient safety, and outcome.
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NCT00790010 ipilimumab + bevacizumab between cohorts Melanoma (III-IV) I safety, tolerability,max tolerated dose 12 November 2008 Active, not recruiting
NCT01950390 ipilimumab + bevacizumab ipilimumab Melanoma (III-IV) II OS 23 September 2013 Active, not recruiting
NCT02420821 atezolizumab + bevacizumab sunitinib mRCC III PD, PFS, OS 15 April 2015 Active, not recruiting
NCT02684006 avelumab + axitinib sunitinib mRCC III PFS, OS 25 January 2016 Active, not recruiting
NCT02853331 pembrolizumab + axitinib sunitinib mRCC III PFS, OS 29 July 2016 Active, not recruiting
NCT03914300 cabozantinib + nivolumab +ipilimumab - Thyroid cancer II ORR 11 April 2019 Recruiting
NCT03990571 axitinib + avelumab - Recurrent/metastaticACC II ORR 17 June 2019 Recruiting




10 July 2019 Recruiting
NCT04170556 regorafenib + nivolumab - HCC I/II Rate of AE 18 November 2019 Recruiting
NCT04213170 sintilimab + bevacizumab - Brain metastasesfrom NSCLC II iPFS, OS, PFS 25 December 2019 Recruiting
NCT04408118 atezolizumab + bevacizumab +paclitaxel - BC, TNBC II PFS 20 May 2020 Recruiting
NCT04493203 nivolumab + axitinib - Melanoma (III-IV) II ORR 22 July 2020 Recruiting
NCT04727307 atezolizumab + RFA + bevacizumab +atezolizumab RFA Small HCC II
Recurrence-free
survival 22 January 2021 Recruiting
NCT04732598 bevacizumab + atezolizumab +paclitaxel
bevacizumab +
paclitaxel BC III PFS 28 January 2021 Recruiting
* Status according to https://clinicaltrials.gov/, accessed on 25 March 2021. Immunotherapy drugs: Anti-PD-1: Pembrolizumab, nivolumab, sintilimab; anti. PD-L1: Atezolizumab, avelumab; anti-CTL4:
Ipilimumab. Anti-angiogenic therapies: Anti-VEGF: Bevacizumab; anti-VEGFRs: Axitinib, sunitinib, regorafenib, cabozantinib. Chemotherapy: Paclitaxel, carboplatin. ACC: Adenoid cystic carcinoma; AE:
Adverse events; BC: Breast cancer; HCC: Hepatocellular carcinoma; iPFS: Intracranial progression free survival; mRCC: Advanced/metastatic renal cell carcinoma; NSCLC: Non-small cell lung cancer; ORR:
Overall response rate; OS: Overall survival; PD: Disease progression; PFS: Progression free survival; RFA: Percutaneous radiofrequency ablation; TNBC: Triple negative breast cancer.
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5. The Potential Use of Other Therapeutic Strategies Targeting Cancer Cells and
Impacting Angiogenesis
The clinical results of the use of anti-angiogenic compounds, alone and in combination
with conventional cancer therapy, are far from the remarkable successes obtained in pre-
clinical settings. Since the efficacy and mechanism of action of the anti-angiogenic drugs
(inhibition vs. normalization of tumor vasculature) is still a matter of debate, new efforts
have been made for the development of new compounds with both anti-tumor and anti-
angiogenic properties. For instance, ivermectin, a FDA-approved anti-parasitic drug for
the treatment of intestinal worm infections, inhibit ovarian, breast, and glioma cancer cells
growth, and promote cancer cell death [164–167] while it also targets angiogenesis through
the inhibition of capillary network formation, proliferation, and survival of human brain
microvascular ECs [167]. In addition, carnosol and carnosic acid, the major components of
rosemary extracts, inhibit tumor cell growth and affect several steps of the angiogenesis
process, as EC differentiation, proliferation, migration, and proteolytic capability [168].
Other compounds, as fucoidan and sulfated galactofucan have been shown to reduce tumor
growth and inhibit tumor angiogenesis, in part through the inhibition of STAT3-regulated
genes, as VEGF, Bcl-xL, and cyclin D1 [169,170].
5.1. ROS-Related Drugs: A Double-Edge Sword
The metabolic remodeling of tumor and tumor associated stromal cells (TASCs)
drive the generation of a pro-oxidant rich-microenvironment, which in turn favors tu-
mor angiogenesis [171–173]. The generation of a pro-oxidant and a pro-angiogenic tu-
mor microenvironment seems to work synergistically in the promotion of the angiogenic
switch and further tumor angiogenesis [174]. The generation of ROS levels in cancer
cells prompted by 27-hydroxycholesterol (27HC) and deferoxamine (DFO) activates STAT-
3/VEGF and ERK1/2/HIF1α signaling pathways, promoting tumor angiogenesis and
metastasis [175,176]. Moreover, in human colon carcinoma cells, the mutant p53 triggers
angiogenesis through the ROS-mediated activation of VEGF and HiF1α [177].
The modulation of the ROS levels in cancer treatment is a double-edged sword. On
one hand, the generation of a pro-oxidant microenvironment in early stages of tumor
development, and at moderate and non-toxic levels, activates cancer cell survival signaling
cascades (e.g., MAPK/ERK1/2, p38, c-Jun N-terminal kinase (JNK), PI3K/Akt) and prompt
tumor angiogenesis through the release of pro-angiogenic factors (e.g., VEGF, FGF) and
extracellular matrix degrading enzymes (e.g., matrix metalloproteinases- MMPs). On the
other hand, the generation of high and toxic ROS levels by chemotherapy and radiotherapy
promotes oxidative stress and further cell death and senescence [178–182]. The in vitro
exposure of breast cancer cells to the antioxidant resveratrol reduce the ROS accumulation,
decreasing paclitaxel-induced cell death [183,184]. The tamoxifen-induced cytotoxicity in
MCF-7 breast cancer cells was regulated by the intracellular concentration of the antioxidant
vitamin C, decreasing the levels of ROS and lipid peroxides [185].
As mentioned, ROS generation in the TME, depending on the levels, can exert pro-
tumorigenic and pro-angiogenic effects or drive oxidative stress-mediated cell death,
pointing out that strategies focused on the modulation of ROS levels and oxidative stress
to impair tumor progression, angiogenesis, and metastasis need to be carefully monitored.
Baicalein, a phenolic flavonoid compound with antioxidant properties, inhibits cancer pro-
liferation and migration, induces cancer cell death, and disrupts the development of tumor
vasculature [186–188]. OptiBerry, a anthocyanins-rich berry extract with antioxidant prop-
erties, shown to inhibit H2O2 and TNFα-induced VEGF expression by keratinocytes and to
diminish the ability of ECs to form hemangioma, suggesting a putative anti-angiogenic,
antioxidant, and anti-cancer effect [189]. Other compounds have also shown strong ROS
scavenging activities and anti-cancer activity, as the polyphenol from T. pallida and white
mulberry (Morus alba) [190]. However, the effects of this compound on the tumor vas-
culature have not been evaluated so far. Contradictory information comes from studies
suggesting that strategies focused on the generation of ROS and further oxidative stress
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induce ECs dysfunction, impairing tumor angiogenesis [191,192]. Although most of the
studies support the angiogenic potential of ROS as a therapeutic target for anti-cancer and
anti-angiogenic therapy, the effects of those strategies on tumor angiogenesis and their
mechanisms of action not only in ECs, but also in the crosstalk between ECs:cancer cells,
need to be explored. Further research to a better understanding of disease-specific ROS
involvement and their potential as anti-tumor strategy will be pivotal for the discovery of
new therapeutic targets and further drug development for cancer treatment.
5.2. β-Adrenergic Drugs: Repurposing Existing Drugs for Anti-Cancer and Anti-Angiogenic
Clinical Purposes
The activation of the β-adrenergic system by catecholamines, epinephrine, and nore-
pinephrine has been related to the tumorigenic processes, as cancer cell proliferation and
apoptosis, and also with vascular events, as angiogenesis [193,194]. In ovarian cancer
patients under social isolation, the increased levels of noradrenaline are correlated with
tumor grade and stage, suggesting the contribution of the β-adrenergic receptors (β-AR)
system in cancer progression [195]. Chronic behavioral stress hormones, as adrenaline
and/or noradrenaline, promote pancreas, breast, colorectum, and prostate cancer progres-
sion [193,196–199]. More recently, the expression of β2-AR has been proposed as a useful
and novel prognostic factor for patients with clear cell renal carcinoma [200]. Besides the
biobehavioral factors that contribute to the activation of β-AR system, some cancer cells
(e.g., pancreatic, lung, colon) are able to synthesize and release adrenaline [201,202].
β-AR signaling activation via adrenaline and/or noradrenaline is implicated in the
promotion of angiogenesis, through the upregulation of pro-angiogenic factors, as VEGF,
IL6, IL8, and MMP2 and 9 and by the upregulation of VEGFR2 [203–205]. In prostate
cancer xenograft models, β-AR signaling promote tumor angiogenesis [193]. The crosstalk
between ECs and cancer cells potentiates tumor angiogenesis mediated by β-AR signaling
pathway, inducing the EC activation of Jagged1/Notch intercellular signaling and the
metabolic shift of ECs from oxidative phosphorylation to aerobic glycolysis, which repre-
sents a critical step during the angiogenic switch [203,206]. Interestingly, in a mice model
of ovarian cancer, dopamine administration (antagonize the effect of stress hormones) in-
hibits tumor angiogenesis and stabilizes the already formed tumor vasculature, enhancing
cisplatin delivery and efficacy [207]. These results reinforce that the activation of the AR
signaling pathway by catecholamines might be a key event in the tumor angiogenesis
cascade.
Considering the modulatory role of β-AR signaling in tumorigenesis, β-blockers
showed a promising anti-angiogenic and anti-cancer therapeutic value. Preclinical and
retrospective studies highlighted the beneficial actions of β-blockers administration in
cancer patients, improving the relapse free survival and decreasing the tumor recurrence,
cancer-specific mortality, and metastasis [208,209]. Moreover, the efficacy of Propranolol,
a first generation non-selective β-AR antagonist (in some tissues inverse agonist), that
acts by competing with catecholamines for the binding to β-adrenergic receptors, was
shown to be effective in the treatment of hemangioma, the most common infantile be-
nign tumor that involves the accumulation, proliferation, and differentiation of aberrant
vascular structures [210–213]. Propranolol demonstrated anti-cancer and anti-angiogenic
pharmacological properties since its administration in breast cancer patients with arterial
hypertension significantly reduced the primary tumor development, nodal/metastatic oc-
currence, and breast cancer-specific mortality [209]; abrogated the VEGF production [214];
inhibited the noradrenaline-induced HIF1α expression in cancer cells [214] and inhibited
the catecholamine-induced signaling between macrophages and ECs [215]. In neuroblas-
toma, β-blockers (carvedilol, nebivolol, and Propranolol) independently of their selectivity,
promoted vincristine-induced tumor regression, in part mediated by the inhibition of
tumor angiogenesis [216]. Controversially, an ex vivo study using aortic rings showed
that β-blockers’ pro-angiogenic or anti-angiogenic activity is independent of their abil-
ity to antagonize catecholamine action. For instance, forskolin (β-AR agonist) a direct
activator of adenylate cyclase that increased AMPc production through β-signaling activa-
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tion, decreases VEGF-mediated microvessel sprouting while increases were observed with
Propranolol, metoprolol, and bisoprolol (2nd generation, β1-AR–selective antagonists),
and while carvedilol (3rd generation, a nonselective β-AR antagonist with additional alfa
blocking activity and antioxidant properties) was unable to affect aortic sprouting [217].
Although it has been suggested that β-blockers could be a putative anti-angiogenic
drug, some studies have failed to observe this association, remaining unclear as to how β-
blockers mechanistically affects and impairs tumor angiogenesis. Moreover, as mentioned,
previous studies demonstrated that inhibitory neurotransmitters induce tumor vessel
normalization, which might suggest that the inhibition of the β-adrenergic system by β-
blockers will promote tumor vessel normalization. This will in turn increase the efficacy of
the delivery of anti-cancer drugs. The favorable safety profile, the low cost and immediate
clinical availability, together with the putative cancer patient welfares point to the benefits
of repositioning an old drug for new clinical purposes.
5.3. The Anti-Angiogenic Modulatory Role of Oxidative Stress and DNA Repair Controllers
As previously mentioned (in Section 5.1), a pro-oxidant rich tumor microenviron-
ment is tightly associated with angiogenesis promotion. Considering that high ROS levels
activate VEGF and HIF1α signaling pathways, several therapeutic strategies have been
developed to target ROS-induced angiogenesis. The generation of free radicals in the
cancer context is not a new topic, since the effect of several chemotherapeutic and radiother-
apeutic strategies are mediated by ROS production, which in turn affect signaling cascades
responsible for cell survival. For instance, the widely used platinum derivatives, such as
carboplatin and cisplatin, increase ROS levels, generating nuclear and mitochondrial DNA
adducts [218,219]. These adducts are then recognized by DNA damage repair pathways,
triggering apoptosis [220]. However, higher ROS are also associated with chemotherapy
resistance [221]. Therefore, the combination of these therapies with ROS modulators (either
pro- or antioxidants) has been proposed [222], but its translation to clinics has been difficult
to apply.
One key signaling molecule that is activated in response to hypoxia is the nuclear factor
erythroid 2 like-2 (Nrf2). This transcription factor is the major one responsible for the redox
balance, controlling the expression of antioxidant-response genes [223]. More recently, the
role of Nrf2 in DNA damage repair has been explored, and some studies have already
shown a potential protective effect of Nrf2 in chemotherapy and radiotherapy-induced
DNA damage [224]. For instance, in lung cancer cell lines, the Nrf2/glutathione-mediated
antioxidant defense pathway plays an important role in conferring resistance to cisplatin,
acting as a good biomarker to predict cisplatin sensitivity [225]. Moreover, Nrf2 also has a
role in radiotherapy resistance, facilitating the repair of induced DNA damage through
the HDR, in a ROS independent manner [226]. Regarding its role in angiogenesis, this
transcription factor is activated by hypoxia and triggers several pathways also activated by
HIF-1α, through different target genes, such as HO-1, a member of the heme oxygenase
family that activates angiogenesis in a VEGF-independent manner [223]. Therefore, tar-
geting Nrf2 or its downstream targets could provide new therapeutic strategies to impair
tumor angiogenesis. Several Nrf2 inhibitors have been studied in the context of cancer
therapy, as reviewed in Panieri and Saso, 2019 [227], including brusatol, a quassinoid
compound extracted from Brucea javanica that was shown to deplete Nrf2 protein levels in
mouse hepatoma cells [228]. Moreover, brusatol can also inhibit HIF1α accumulation under
hypoxia in colon carcinoma cells, abrogating its signaling pathway [229]. Even though
these are promising results, it is important to note that some controversy remains on the
impact of NRF2 pharmacological modulation on tumor growth [230].
In a study developed by Pastukh et al., an oxidative DNA damage and repair mecha-
nism in the VEGF promoter was described, showing a surprising target of ROS generated
by hypoxia [231]. ROS were able to cause modifications in the hypoxic responsive elements
(HRE) present in the VEGF promoter, thereby increasing VEGF expression through the
involvement of the base excision DNA repair (BER) pathway. By chromatin immunopre-
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cipitation analysis, it was found that HIF1 and BER enzymes (8-oxoguanine glycosylase
1, Ogg1, and redox effector factor-1, Ref-1) were bound on HRE, and DNA strand breaks
were introduced. Accordingly, inhibition of BER by downregulation of Ogg1 decreased
VEGF expression [231].
Moreover, Kaplan et al. showed in an in vivo ovarian cancer model that cediranib,
an anti-angiogenic agent (anti-VEGFR), is able to suppress the expression of homology-
directed DNA repair (HDR) factors [232]. This effect occurred not only in a hypoxic context,
in which hypoxia is able to inhibit HDR by several mechanisms [233], but also in normoxic
conditions through the down-regulation of BRCA1/2 and RAD51 genes [232].
One emerging class of tumor therapeutic drugs is poly(ADP-ribose) polymerase
(PARP) inhibitors, which target DNA damage repair mechanisms [234]. PARPs belong
to BER system and their inhibition promotes the accumulation of single-strand DNA
breaks, which will force the occurrence of double-strand DNA breaks. This way PARPs
inhibition will account for the accumulation of single-strand and double-strand DNA
lesions and consequently it will also affect the homology-directed DNA repair (HDR)
system. Therefore, tumors with BRCA 1/2 mutations are more sensitive to this treatment
once the mutated proteins are incapable of repairing double-strand DNA breaks (HDR
deficit). Initially, this therapy was only applied to breast and ovarian cancer tumors with
this alteration, but its efficacy was later showed in subsets of tumors without HDR deficit.
Therefore, the combination of PARP inhibitors with chemo- and radiotherapy is currently
under phase II trial (ANLOLA, NCT04566952).
Interestingly, PARP inhibition also affects ECs. A PARP inhibitor, GPI, was shown
to abrogate EC migration and the formation of tube-like structures, thus impairing an-
giogenesis, without compromising ECs viability, both in vitro and in vivo [235]. In the
last years, some clinical trials were organized to explore the impact of the combination of
anti-angiogenic therapies with PARP inhibitors in cancer treatment. For instance, a phase
I/II study, investigating the combination of cediranib and olaparib (PARP inhibitor) in
women with recurrent ovarian and breast cancer (NCT01116648) has already shown some
promising results, improving PFS in women with recurrent platinum-sensitive ovarian
cancer [236]. Another ongoing phase I/II trial is evaluating the PARP inhibitor niraparib
tolerability and efficacy in combination with bevacizumab vs. niraparib alone in patients
with platinum-sensitive epithelial ovarian cancer (AVANOVA, NCT02354131). Some re-
sults already available show a promising activity of this combination therapy resulting in
improvement in PFS, regardless of the HDR deficiency status or the chemotherapy-free
interval [237,238]. More recently, a following phase III trial is comparing the efficacy of nira-
parib and bevacizumab combination, with the standard of care treatment (NCT03806049).
It is important to notice that ROS-induced DNA damage does not only occur in
the nucleus, but also at the mitochondrial level. Mitochondrial damage, resulting in
mitochondrial DNA release to cytosol, is able to dysregulate the Hippo-Yap pathway [239].
This pathway is a key inhibitor of angiogenesis [231,232]. A study with an aging rat
model showed that mitochondrial DNA-deficient kidney cells failed to upregulate VEGF
in response to hypoxia due to mitochondrial dysfunction, which contributes to impaired
angiogenesis [240].
Therefore, the relation between ROS-induced DNA damage and angiogenesis has
already provided some new potential therapeutic combinations, which needs to be further
explored mechanistically and in clinical settings.
6. Final Remarks
The failure of anti-VEGF strategies in the control of cancer can be in part related to
two major factors. On one hand, the fact that the precise molecular mechanisms of cancer
neo-angiogenesis still have secrets. On the other hand, because the abrogation of blood
supply will also restrict drug delivery to the tumor, decrease their efficacy, and promote
drug resistance [9]. In line, the paradox in the use of anti-angiogenic drugs arises from new
findings showing that instead of eradicating blood supply, strategies focused on restoring
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the tumor vessels normalization would increase the delivery of therapeutic agents to cancer
cells, improving the therapeutic efficacy and impairing cancer cells spread [125].
Interestingly, simvastatin, a statin with antioxidant properties, has been showed to
reduce hypoxia-induced endothelium leakage and decrease ROS-induced HIF1α and VEGF
expression, attenuating VEGF-derived tumor vessel hyperpermeability and improving
cisplatin and cyclophosphamide efficacy [241]. In a theoretical scenario, cancer treatment
might rely on multi-mechanisms targeting strategies focused on the induction of cancer
cells death and in the promotion of tumor vascular regression or stabilization events
(Figure 3). At the same time, these strategies will transform the remaining vessels into a
more functional vascular network with decreased permeability, promoting drug delivery
and impairing metastasis. Cancer cells under a certain threshold have adaptive antioxidant
mechanisms controlling oxidative stress, however, above this threshold, ROS accumulation
disrupts redox homeostasis and causes severe damage in cancer cells, ultimately leading to
cell death [242]. Given these results, strategies to enhance lethal ROS production in cancer
cells have a promising anti-cancer effect.
Figure 3. Increased oxidative stress activates endothelial cells (ECs) and kills cancer cells, and antioxidant mechanisms
can stabilize vessels and improve anti-cancer chemotherapy. (A) A pro-angiogenic oxidative microenvironment, through
the increased generation of ROS, the accumulation of lipid peroxides and glutathione (GSH) depletion is implicated in the
promotion of ECs hyperactivation, vessels leakiness, and cancer cells migration and intravasation. (B) ROS scavenging
activity is anti-angiogenic, since on one hand, it impairs the ECs activation, and on other hand, it promotes vessels
normalization, pivotal to impair metastasis and improve the delivery of chemotherapeutic agents.
Angiogenesis-based cancer therapeutic strategies must accompany the microenviron-
mental and metabolic drift, which tumor cells (malignant and stromal) undergo in order to
progress. Therefore, by presenting different metabolic patterns and adaptive redox mecha-
nisms, ECs and cancer cells would present a disparate behavior, and whereas oxidative
stress activates ECs and stabilizes blood vessels that will be more competent in drugs
delivery; cancer cells would be endangered by oxidative stress and by drugs aggression.
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